Table 2.

Studies on neoadjuvant imatinib therapy for gastrointestinal stromal tumors

Ref.	Clinical trial	Yr	Design	Endpoint	Cases	Agent/Dose	Patients	Duration	RR	R0 rate	Adjuvant imatinib	PFS	OS
Prospective study
Eisenberg et al[39]	RTOG0132 trial	2009	Phase II	RFS	30 (all; 52)	Imatinib/600 mg	GIST (> 5 cm)	8-12 wk	7%	77%	24 mo	2-yr PFS; 83%	2-yr OS; 93%
Wang et al[40]	RTOG0132 (long follow up)	2012			31 (all; 53)							5-yr PFS; 57%	5-yr OS; 77%
Doyon et al[41]		2012	Phase II	RR	14	Imatinib/400 mg	Locally advanced GIST	6 mo	43%	79%	12 mo	4-yr DFS; 64%	4-yr OS; 100%
Kurokawa et al[42]	Asia	2017	Phase II	PFS	53	Imatinib/400 mg	Gastric GIST (> 10 cm)	6-9 mo	62%	91%	36 mo	2-yr PFS; 89%	2-yr OS; 98%
Retrospective study
Blesius et al[35]	BFR14 trial	2011	Subset phase III	-	25	Imatinib/400 mg	Locally advanced GIST	4.2 mo (median)	60%	32%	13-24 mo	3-yr PFS; 67%	3-yr OS; 89%
Rutkowski et al[36]	EORTC	2012	Database	-	161	Imatinib/400 mg	Locally advanced GIST	40 wk (median)	80%	83%	At least 1 yr (56%)	5-yr DFS; 65%	5-yr DSS; 95%
Tielen et al[37]		2013	Database	PFS/OS	57	Imatinib/400 mg	GIST (> 5 cm) and/or ill-located for surgery	8 mo (median)	83%	84%	1, 2 yr or lifelong (58%)	5-yr PFS; 77%	5-yr OS; 88%

RFS: Relapse-free survival; RR: Response rate; PFS: Progression-free survival; OS: Overall survival; DSS: Disease-specific survival.